243 related articles for article (PubMed ID: 27739168)
1. The heparin-binding domain of HB-EGF as an efficient cell-penetrating peptide for drug delivery.
Luo Z; Cao XW; Li C; Wu MD; Yang XZ; Zhao J; Wang FJ
J Pept Sci; 2016 Nov; 22(11-12):689-699. PubMed ID: 27739168
[TBL] [Abstract][Full Text] [Related]
2. Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity.
Lv Q; Yang XZ; Fu LY; Lu YT; Lu YH; Zhao J; Wang FJ
Protein Expr Purif; 2015 Jul; 111():9-17. PubMed ID: 25797209
[TBL] [Abstract][Full Text] [Related]
3. A novel trichosanthin fusion protein with increased cytotoxicity to tumor cells.
Lin B; Yang XZ; Cao XW; Zhang TZ; Wang FJ; Zhao J
Biotechnol Lett; 2017 Jan; 39(1):71-78. PubMed ID: 27714558
[TBL] [Abstract][Full Text] [Related]
4. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
Chen WW; Zhang HR; Huang ZG; Zhou ZY; Lou QW; Jiang XY; Zhu ZH
Protein Expr Purif; 2021 Sep; 185():105893. PubMed ID: 33933613
[TBL] [Abstract][Full Text] [Related]
5. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].
Zhang LL; Ding Q; Zhan JB
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 May; 39(3):264-71. PubMed ID: 20544988
[TBL] [Abstract][Full Text] [Related]
6. Expression of Momordica charantia MAP30 and its antitumor effect on bladder cancer cells.
Hlin H; Zhi-Guo Z; Cong-Hui H; Yan Z; Qing L; Bo J; Hou-Guang H; Jun-Jie Z; Pei-Ying Z
Minerva Urol Nefrol; 2016 Jun; 68(3):275-81. PubMed ID: 25517785
[TBL] [Abstract][Full Text] [Related]
7. Scalable Production of Recombinant Membrane Active Peptides and Its Potential as a Complementary Adjunct to Conventional Chemotherapeutics.
Rothan HA; Ambikabothy J; Abdulrahman AY; Bahrani H; Golpich M; Amini E; A Rahman N; Teoh TC; Mohamed Z; Yusof R
PLoS One; 2015; 10(9):e0139248. PubMed ID: 26418816
[TBL] [Abstract][Full Text] [Related]
8. Enhancing tumor-specific intracellular delivering efficiency of cell-penetrating peptide by fusion with a peptide targeting to EGFR.
Nguyen LT; Yang XZ; Du X; Wang JW; Zhang R; Zhao J; Wang FJ; Dong Y; Li PF
Amino Acids; 2015 May; 47(5):997-1006. PubMed ID: 25655386
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anticancer effect of MAP30-S3 by cyclosproin A through endosomal escape.
Song ZT; Zhang LW; Fan LQ; Kong JW; Mao JH; Zhao J; Wang FJ
Anticancer Drugs; 2018 Sep; 29(8):736-747. PubMed ID: 29912010
[TBL] [Abstract][Full Text] [Related]
10. Α-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells.
Fan X; He L; Meng Y; Li G; Li L; Meng Y
Mol Med Rep; 2015 May; 11(5):3553-8. PubMed ID: 25573293
[TBL] [Abstract][Full Text] [Related]
11. Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.
Meng Y; Liu S; Li J; Meng Y; Zhao X
Int J Nanomedicine; 2012; 7():3133-42. PubMed ID: 22802682
[TBL] [Abstract][Full Text] [Related]
12. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
[TBL] [Abstract][Full Text] [Related]
13. Fusion of protegrin-1 and plectasin to MAP30 shows significant inhibition activity against dengue virus replication.
Rothan HA; Bahrani H; Mohamed Z; Abd Rahman N; Yusof R
PLoS One; 2014; 9(4):e94561. PubMed ID: 24722532
[TBL] [Abstract][Full Text] [Related]
14. Effectively enhancing cytotoxic and apoptotic effects of alpha-momorcharin by integrating a heparin-binding peptide.
Tan MJ; Cao XW; Li PF; Zhai YZ; Zhou Y; Liu YJ; Zhao J; Wang FJ
Biotechnol Appl Biochem; 2017 Nov; 64(6):918-926. PubMed ID: 28090686
[TBL] [Abstract][Full Text] [Related]
15. The cell-penetrating peptide domain from human heparin-binding epidermal growth factor-like growth factor (HB-EGF) has anti-inflammatory activity in vitro and in vivo.
Lee JY; Seo YN; Park HJ; Park YJ; Chung CP
Biochem Biophys Res Commun; 2012 Mar; 419(4):597-604. PubMed ID: 22342671
[TBL] [Abstract][Full Text] [Related]
16. MAP30 inhibits autophagy through enhancing acetyltransferase p300 and induces apoptosis in acute myeloid leukemia cells.
Qian S; Sun L; Li J; Wu J; Hu G; Han Y; Yu K; Zhang S
Oncol Rep; 2016 Jun; 35(6):3705-13. PubMed ID: 27035419
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anti-tumor activity of trichosanthin after combination with a human-derived cell-penetrating peptide, and a possible mechanism of activity.
Lu YZ; Li PF; Li YZ; Luo F; Guo C; Lin B; Cao XW; Zhao J; Wang FJ
Fitoterapia; 2016 Jul; 112():183-90. PubMed ID: 27050721
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Triterpenoid Saponins Reveals Insights into Structural Features Associated with Potent Protein Drug Enhancement Effects.
Cao XW; Wang FJ; Liew OW; Lu YZ; Zhao J
Mol Pharm; 2020 Feb; 17(2):683-694. PubMed ID: 31913047
[TBL] [Abstract][Full Text] [Related]
19. High-level expression and purification of soluble bioactive recombinant human heparin-binding epidermal growth factor in Escherichia coli.
Khalili M; Soleyman MR; Baazm M; Beyer C
Cell Biol Int; 2015 Jul; 39(7):858-64. PubMed ID: 25712700
[TBL] [Abstract][Full Text] [Related]
20. Ribosome-inactivating Protein MAP30 Isolated from
Zhou Y; Yang D; Qiang Z; Meng Y; Li R; Fan X; Zhao W; Meng Y
Recent Pat Anticancer Drug Discov; 2024; 19(2):223-232. PubMed ID: 36330636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
